Buchumschlag

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Thaler, Josef (VerfasserIn) , Hofheinz, Ralf-Dieter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 29 September 2012
In: BMC cancer
Year: 2012, Jahrgang: 12
ISSN:1471-2407
DOI:10.1186/1471-2407-12-438
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/1471-2407-12-438
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/1471-2407-12-438
Volltext
Verfasserangaben:Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños and Claus-Henning Köhne
Beschreibung
Zusammenfassung:Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report additional descriptive tolerability and quality of life data from this trial.
Beschreibung:Gesehen am 15.10.2018
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-12-438

Ähnliche Einträge